Document ID: chunk:federal_register_of_legislation:F2023C01042:reg:9:p2
Version: federal_register_of_legislation:F2023C01042
Segment Type: reg
Provision Reference: reg 9 (pt 2/5)
Character Range: 9492–12600

parkinsonism;
(l)            having neurosyphilis at the time of the clinical onset of secondary parkinsonism;
Note: neurosyphilis is defined in the Schedule 1 - Dictionary.
(m)        having neurocysticercosis at the time of the clinical onset of secondary parkinsonism;
(n)          inhaling carbon disulphide vapour in an enclosed space, or having cutaneous contact with carbon disulphide, for a cumulative period of at least 500 hours, within the ten years before the clinical onset of secondary parkinsonism;
(o)          inhaling or ingesting methanol or ethylene glycol, and having clinical, haematological or biochemical evidence of methanol or ethylene glycol intoxication, within the six weeks before the clinical onset of secondary parkinsonism;
(p)          being exposed to manganese as specified for a cumulative period of at least 500 hours, within the ten years before the clinical onset of secondary parkinsonism;
Note:  being exposed to manganese as specified is defined in the Schedule 1 - Dictionary.
(q)          having clinical or biochemical evidence of manganese intoxication while receiving total parenteral nutrition or maintenance haemodialysis, at the time of the clinical onset of secondary parkinsonism;
Note: total parenteral nutrition is defined in the Schedule 1 - Dictionary.
(r)           inhaling, ingesting or having cutaneous contact with cyanide, and having clinical, haematological or biochemical evidence of cyanide intoxication, within the six weeks before the clinical onset of secondary parkinsonism;
(s)           having an injection containing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) within the six weeks before the clinical onset of secondary parkinsonism;
(t)            using the drug methcathinone (ephedrone) within the six weeks before the clinical onset of secondary parkinsonism;
(u)          taking a drug or a drug from a class of drugs from the specified list of drugs, for a continuous period of at least 14 days within the six weeks before the clinical onset of secondary parkinsonism;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(v)          having a disorder of calcium metabolism from the specified list of disorders of calcium metabolism at the time of the clinical onset of secondary parkinsonism;
Note: specified list of disorders of calcium metabolism is defined in the Schedule 1 - Dictionary.
(w)        having cirrhosis of the liver at the time of the clinical onset of secondary parkinsonism;
(x)          having chronic renal failure due to diabetes mellitus at the time of the clinical onset of secondary parkinsonism;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
(y)          having a disease from the specified list of autoimmune diseases at the time of the clinical onset of secondary parkinsonism; or
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(z)          having a paraneoplastic encephalomyelitis at the time of the clinical onset of secondary parkinsonism;
(3)          having an episode of acute cholinergic poisoning